Rituximab in PMR. Intriguing proof of concept (SB?) RCT (1:1, total n=47 (recent dx 38/relapsing 9)) 17w rapid PNL taper ritux 1g x1 21w: steroid-free remission: 48% v 21% PNL ≤5mg/d: 100% v 54% effect mainly from recent dx pts We do need options! POS0343 #EULAR2021 @RheumNow https://t.co/g6xJekY92O

HUR-BIO real life data, PsA pts started bDMARDs w/in 18 mo of dx vs almost 3x later in RA pts (tended to remain on csDMARDs.) This distinction may be explained by synthetic DMARDs on activity differences between the RA & PsA. Abstract #POS0633 #EULAR2021 https://t.co/VkkF28jm2f https://t.co/IkfGdZYNY3

• http://ow.ly/zQ7B50F3Gag

Poster #POS0633 detailed HUR-BIO PsA pts started bDMARDs w/in 18 months of dx vs, on ave, 3x longer to start bDMARDs in RA pts in real life data. What do you drugs do you start in your PsA pts after dx? Feel free to detail me below! #EULAR2021 @RheumNow

Dr Marsman presents positive RCT of Rituximab in PMR. GC-free remission 48% vs 21% (p=0.049) GC<=5mg 100% vs 47% (p=0.005) @RheumNow #EULAR2021 Abstr#POS0343 https://t.co/tjkKTS6DMN

#POS0022 prosp study of CTZ pregnancies: 1392 preg w/1425 outcomes @UCBUSA database 88.4% live births, 10.5% preg loss, 0.8% still birth 2.4% congen malform (w/2.1% major) Preg loss⬅️Crohn's, NSAIDS, MTX Preterm labor⬅️GCs, maternal infx ⬇️birth wt⬅️RA & GCs @rheumnow #EULAR2021 https://t.co/qnNcDIz8Ge

Real-world data from PsABio: 🚺generally start biologics in a worse PsA state than🚹. Although treatment improvements were similar between sexes, 🚺remained in worse health at 1 yr, and stopped/switched bDMARD earlier. Abstract #OP0232 #EULAR2021 @RheumNow https://t.co/oIGu0HzisQ https://t.co/uLnYOq8ypx

• http://ow.ly/OJzg50F3Gi5

#EULAR2021 and EULAR IQ Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021. https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg

• https://bit.ly/3fS5SJX

KEEPsAKE 2: Risankizumab RCT in Bio-IR or csDMARD-IR active PsA. Primary endpoint ACR20 W24 met with 51.3% vs 26.5% in PBO group (P < .001) and ACR50 26.3% vs 9.3%. No particular safety signal. #OP0228 @Rheumnow #EULAR2021 https://t.co/HZv8qoc4sz

Serious infections and BioDMARDs: what is the confounding factor? BSRBR-RA: 33,916 RA treated w/ BioDMARDs with 62,532 years of follow-up, 2036 SI. HR of SI no longer different among BioDMARDs when adjusted for the line of therapy! #OP0241@Rheumnow #EULAR2021 https://t.co/UG9WrXP7RD

Is Rituximab and Belimumab the Combination to Beat Lupus? by Dr. Eric Dein (@ejdein1) #EULAR2021 On day 2 of EULAR , Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab. https://t.co/r4aNG7KR5h https://t.co/nppgRytnlr

• https://bit.ly/3z5kNrB

Presenting now at #EULAR2021 #COVID19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with #rituximab: a cohort study https://t.co/QTGkiMcC2d https://t.co/DJB6GooPuJ

• DEFINE_ME